Total Payments
$15,870
2024 Payments
$774.44
Companies
8
Transactions
15
Medicare Patients
12,506
Medicare Billing
$459,575

Payment Breakdown by Category

Consulting$14,563 (91.8%)
Food & Beverage$859.59 (5.4%)
Research$447.50 (2.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $14,563 8 91.8%
Food and Beverage $859.59 6 5.4%
Unspecified $447.50 1 2.8%

Payments by Type

General
$15,422
14 transactions
Research
$447.50
1 transactions

Top Paying Companies

Company Total Records Latest Year
Siemens Medical Solutions USA, Inc. $4,340 2 $0 (2022)
Merck Sharp & Dohme Corporation $3,773 4 $0 (2021)
Otsuka Pharmaceutical Development & Commercialization, Inc. $3,750 1 $0 (2022)
Otsuka America Pharmaceutical, Inc. $2,700 1 $0 (2023)
E.R. Squibb & Sons, L.L.C. $691.55 3 $0 (2024)
ABBVIE INC. $250.00 2 $0 (2024)
FUJIFILM Healthcare Americas Corporation $201.94 1 $0 (2024)
Boston Scientific Corporation $163.60 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $774.44 3 E.R. Squibb & Sons, L.L.C. ($447.50)
2023 $2,989 3 Otsuka America Pharmaceutical, Inc. ($2,700)
2022 $5,750 2 Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,750)
2021 $6,113 5 Merck Sharp & Dohme Corporation ($3,773)
2019 $119.05 1 E.R. Squibb & Sons, L.L.C. ($119.05)
2018 $125.00 1 E.R. Squibb & Sons, L.L.C. ($125.00)

All Payment Transactions

15 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
05/08/2024 E.R. Squibb & Sons, L.L.C. OPDUALAG (Drug) Cash or cash equivalent $447.50 Research
Study: PhII Nivo vs. Nivo+Rela IO nave 2L+ HCC - A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors • Category: Oncology
04/30/2024 ABBVIE INC. VRAYLAR (Drug) Food and Beverage In-kind items and services $125.00 General
Category: NEUROSCIENCE
04/04/2024 FUJIFILM Healthcare Americas Corporation SYNAPSE 3D (Device) Food and Beverage In-kind items and services $201.94 General
Category: Medical Device
12/13/2023 ABBVIE INC. VRAYLAR (Drug) Food and Beverage In-kind items and services $125.00 General
Category: NEUROSCIENCE
06/06/2023 Otsuka America Pharmaceutical, Inc. JYNARQUE (Drug) Consulting Fee Cash or cash equivalent $2,700.00 General
Category: NEPHROLOGY
03/31/2023 Boston Scientific Corporation Food and Beverage In-kind items and services $163.60 General
Category: General - Therapies_IC
09/07/2022 Otsuka Pharmaceutical Development & Commercialization, Inc. Consulting Fee Cash or cash equivalent $3,750.00 General
05/04/2022 Siemens Medical Solutions USA, Inc. Consulting Fee Cash or cash equivalent $2,000.00 General
12/07/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $1,290.00 General
Category: ONCOLOGY
11/17/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $175.00 General
Category: ONCOLOGY
08/18/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $2,220.00 General
Category: ONCOLOGY
08/02/2021 Siemens Medical Solutions USA, Inc. Consulting Fee Cash or cash equivalent $2,340.00 General
07/20/2021 Merck Sharp & Dohme Corporation KEYTRUDA (Biological) Consulting Fee Cash or cash equivalent $87.50 General
Category: ONCOLOGY
11/19/2019 E.R. Squibb & Sons, L.L.C. OPDIVO (Biological) Food and Beverage Cash or cash equivalent $119.05 General
Category: Oncology
01/16/2018 E.R. Squibb & Sons, L.L.C. OPDIVO (Biological) Food and Beverage Cash or cash equivalent $125.00 General
Category: Oncology

Research Studies & Clinical Trials

Study Name Company Amount Records
PhII Nivo vs. Nivo+Rela IO nave 2L+ HCC - A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors E.R. Squibb & Sons, L.L.C. $447.50 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 32 3,309 9,649 $1.0M $109,454
2022 29 3,122 8,946 $985,258 $111,774
2021 30 2,945 7,811 $895,441 $120,516
2020 25 3,130 10,766 $882,540 $117,832
Total Patients
12,506
Total Services
37,172
Medicare Billing
$459,575
Procedure Codes
152

All Medicare Procedures & Services

152 procedure records from CMS Medicare Utilization — Page 1 of 7

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
71045 X-ray of chest, 1 view Facility 2023 1,255 2,086 $104,300 $16,287 15.6%
74183 Mri scan of abdomen before and after contrast Office 2023 31 32 $113,010 $10,612 9.4%
74177 Ct scan of abdomen and pelvis with contrast Facility 2023 118 118 $48,380 $8,984 18.6%
74176 Ct scan of abdomen and pelvis without contrast Facility 2023 92 95 $37,050 $7,154 19.3%
74183 Mri scan of abdomen before and after contrast Facility 2023 77 80 $44,000 $6,908 15.7%
72197 Mri scan of pelvis before and after contrast Office 2023 21 21 $84,400 $5,965 7.1%
71250 Ct scan of chest without contrast Facility 2023 130 132 $92,400 $5,883 6.4%
74177 Ct scan of abdomen and pelvis with contrast Office 2023 18 18 $38,700 $4,929 12.7%
71046 X-ray of chest, 2 views Facility 2023 449 467 $23,350 $4,131 17.7%
74178 Ct scan of abdomen and pelvis before and after contrast Office 2023 12 12 $33,950 $4,102 12.1%
71260 Ct scan of chest with contrast Facility 2023 80 81 $71,280 $3,926 5.5%
72197 Mri scan of pelvis before and after contrast Facility 2023 30 32 $19,200 $2,943 15.3%
76770 Complete ultrasound scan behind abdominal cavity Facility 2023 92 92 $32,200 $2,816 8.7%
93970 Ultrasound study of arm or leg veins with compression and maneuvers Facility 2023 82 83 $22,130 $2,498 11.3%
74174 Ct scan of blood vessels of abdomen and pelvis with contrast Facility 2023 23 23 $11,270 $2,034 18.0%
74178 Ct scan of abdomen and pelvis before and after contrast Facility 2023 23 23 $10,810 $1,990 18.4%
76700 Complete ultrasound scan of abdomen Facility 2023 56 56 $21,280 $1,840 8.6%
93971 Ultrasound study of one arm or leg veins with compression and maneuvers Facility 2023 88 92 $14,720 $1,812 12.3%
74018 X-ray of abdomen, 1 view Facility 2023 193 223 $11,150 $1,745 15.6%
76705 Limited ultrasound scan of abdomen Facility 2023 62 64 $17,920 $1,591 8.9%
71260 Ct scan of chest with contrast Office 2023 13 13 $16,860 $1,374 8.2%
93880 Ultrasound of both sides of head and neck blood flow Facility 2023 34 34 $8,840 $1,206 13.6%
76770 Complete ultrasound scan behind abdominal cavity Office 2023 12 12 $14,880 $1,167 7.8%
76776 Ultrasound scan of transplanted kidney Facility 2023 26 29 $10,440 $939.46 9.0%
A9585 Injection, gadobutrol, 0.1 ml Office 2023 43 3,318 $33,180 $875.66 2.6%

About Dr. Jasnit Makkar, M.D

Dr. Jasnit Makkar, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Valhalla, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2010. The National Provider Identifier (NPI) number assigned to this provider is 1811213358.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jasnit Makkar, M.D has received a total of $15,870 in payments from pharmaceutical and medical device companies, with $774.44 received in 2024. These payments were reported across 15 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($14,563).

As a Medicare-enrolled provider, Makkar has provided services to 12,506 Medicare beneficiaries, totaling 37,172 services with total Medicare billing of $459,575. Data is available for 4 years (2020–2023), covering 152 distinct procedure/service records.

Practice Information

Products in Payments

  • KEYTRUDA (Biological) $3,773
  • JYNARQUE (Drug) $2,700
  • OPDUALAG (Drug) $447.50
  • VRAYLAR (Drug) $250.00
  • OPDIVO (Biological) $244.05
  • SYNAPSE 3D (Device) $201.94

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Valhalla